<DOC>
	<DOCNO>NCT00676845</DOCNO>
	<brief_summary>This study analyse dose-dependent effect olmesartan medoxomil change arterial stiffness subject hypertension metabolic syndrome</brief_summary>
	<brief_title>Study Determine Olmesartan Medoxomil Has Potential Benefit Cardiovascular System Terms Arterial Protection</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Male female outpatient Age great equal 18 year less equal 75 year Hypertension metabolic syndrome define , accord ATP III/IDF 2005 ESH/ESC 2007 definition , BP great equal 130/85 mmHg &lt; 150/95 mmHg ( i.e . untreated high normal BP `` low range '' mild hypertension ) least 2 follow trait : Abdominal obesity ( waist circumference &gt; 102 cm men &gt; 88 cm woman ) Triglyceride level great equal 150 mg/dL High density lipoprotein ( HDL ) &lt; 40 mg/dL men &lt; 50 mg/dL woman Fasting blood glucose great equal 110 mg/dL &lt; 126 mg/dL ( i.e . type 2 diabetes ) No antihypertensive treatment treatment one antihypertensive medication within last 3 month . Note : treatment angiotensin II receptor blocker ( ARB ) angiotensinconverting enzyme inhibitor ( ACE ) allow within last 6 month . Pregnant lactate female ( prerequisite female subject childbearing potential : adequate contraception ) Type 1 type 2 diabetes `` High range '' mild hypertension ( i.e . systolic blood pressure [ SBP ] : 150 &lt; 160 mmHg /or diastolic blood pressure [ DBP ] : 95 &lt; 100 mmHg ) Moderate ( SBP : 160 179 mmHg DBP : 100 109 mmHg ) , severe ( SBP : great equal 180 mmHg and/or great equal 110 mmHg ) , resistant ( hypertension resistant treatment ) hypertension Secondary hypertension aetiology , renal disease , pheochromocytoma , Cushing 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Arterial stiffness</keyword>
	<keyword>Vascular protection</keyword>
</DOC>